Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon looks to move cognitive disorders drug into clinic
Upon clearance by the regulator, Lexicon intends to initiate a phase I clinical trial of LX6171 in healthy volunteers to assess the compound’s safety, tolerability and pharmacokinetics. In
Upon clearance by the regulator, Lexicon intends to initiate a phase I clinical trial of LX6171 in healthy volunteers to assess the compound’s safety, tolerability and pharmacokinetics. In
It is hoped that patients treated with Miraxion at a dose of 2g per day (1g twice daily) for six months will demonstrate significant improvements in their motor
Hypogonadism is a condition that is estimated to affect approximately 20% of the US male population over age 50. It is characterized by reduced or deficient secretion of
Since receiving approval to initiate the study in the UK recently, the first three patients have been treated. Pharmos expects to complete the trial in the third quarter
Tysabri was pulled from the US market last year after three patients taking the drug developed progressive multifocal leukoencephalopathy (PML), a rare and usually fatal brain disease. The
Sprycel (dasatinib) is the first approved oral tyrosine kinase inhibitor predicted to bind to multiple conformations of the ABL kinase based on modeling studies. The drug's effectiveness is
Wyeth is seeking marketing approval for Lybrel, an investigational low dose combination oral contraceptive for women have no known contraindications for this method of contraception. If approved, this
Therion announced that the 255-patient trial did not meet its primary efficacy endpoint of improving overall survival compared with palliative chemotherapy or best supportive care, and said that
This agreement follows the successful completion of an exploratory study performed with the MicroDose dry powder inhaler (DPI). Under the terms of the agreement, including the initial payment,
Genoptix is known for its focus on providing high-quality and personalized clinical esoteric services to hematologists/oncologists, which aid in the evaluation and management of hematomalignancies. In addition, Genoptix